CEQUA 0.09 % — DIN 02512629
CYCLOSPORINE : 0.09 % · SUN PHARMACEUTICAL INDUSTRIES LIMITED · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is CEQUA?
CEQUA 0.09 % contains CYCLOSPORINE : 0.09 %. It is listed in the Health Canada Drug Product Database under DIN 02512629, held by SUN PHARMACEUTICAL INDUSTRIES LIMITED, supplied as SOLUTION for OPHTHALMIC administration. Health Canada currently lists it as marketed, status dated 08-Dec-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CEQUA used for?
CEQUA (cyclosporine ophthalmic solution 0.09% w/v) is indicated to increase tear production in patients with moderate to severe keratoconjunctivitis sicca (dry eye).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Ciclosporin cost around the world?
Ciclosporin is listed on 11 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 10 | 48 | AUD███.██ |
| Saudi Arabia | public | 11 | 13 | SAR███.██ |
| Greece | producer price (ex-factory) | 10 | 10 | EUR███.██ |
| Iceland | max wholesale | 5 | 10 | ISK███.██ |
| United Arab Emirates | public | 6 | 7 | AED███.██ |
| South Africa | single exit price | 4 | 7 | ZAR███.██ |
| Bahrain | retail (max) | 2 | 6 | BHD███.██ |
| Romania | max producer price | 3 | 5 | RON███.██ |
| Austria | KVP (Kassenverkaufspreis) | 2 | 2 | EUR███.██ |
| Czechia | max producer price (ex-factory) | 1 | 1 | CZK███.██ |
| Hungary | producer price (ex-factory) | 1 | 1 | HUF███.██ |
110 pack listings across 55 brand entries and 9 price bases, refreshed 08 Sep 2026. Ranges span every Ciclosporin pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Ciclosporin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
3 holders have a Canadian DIN containing Ciclosporin, across 4 DINs, of which 4 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ABBVIE CORPORATION | 2 | 2 | RESTASIS, RESTASIS MULTIDOSE | Sourceable in Canada |
| SUN PHARMACEUTICAL INDUSTRIES LIMITED | 1 | 1 | CEQUA | Sourceable in Canada |
| TEVA CANADA LIMITED | 1 | 1 | TEVA-CYCLOSPORINE | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 0.09 % |
|---|---|
| Dosage form | SOLUTION |
| Route | OPHTHALMIC |
| Pack configuration (monograph) | CEQUA is packaged in sterile, preservative - free, single - use vials. Each vial contains 0.25 mL fill in a 0.9 mL LDPE vial; 10 vials (2 cards of 5 vials) are packaged in a polyfoil aluminum pouch; 6 pouches are packaged in a box. The entire contents of each box of 60 vials must be dispensed intact. |
| Storage | CEQUA should be stored at room temperature (15°C to 25°C). Do not freeze. Keep out of the sight and reach of children. Store single - use vials in the original foil pouch. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Ciclosporin |
|---|---|
| ATC code | S01XA18 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02512629 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2512629 |
| Brand name | CEQUA |
| Generic / active ingredient | CYCLOSPORINE : 0.09 % |
| Market authorization holder | SUN PHARMACEUTICAL INDUSTRIES LIMITED |
| Health Canada schedule | Prescription |
| ATC code | S01XA18 |
| ATC anatomical main group | S — Sensory organs |
| ATC therapeutic subgroup | S01XA |
| Current status | MARKETED |
| Status date | 08-Dec-2022 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
4 of 4 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| RESTASIS | 0.05 % | EMULSION | ABBVIE CORPORATION | MARKETED | 02355655 |
| RESTASIS MULTIDOSE | 0.05 % | EMULSION | ABBVIE CORPORATION | MARKETED | 02476835 |
| TEVA-CYCLOSPORINE | 0.05 % | EMULSION | TEVA CANADA LIMITED | MARKETED | 02462486 |
2 · Same class — other molecules in ATC S01XA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Artificial Tears And Other Indifferent Preparations. | ALCON TEARS 0.5% · ALCON TEARS 1% · AMO ENDOSOL EXTRA · AMO ENDOSOL SOLUTION · +84 more | 94 | 26 | Yes |
| Ciclosporin | CEQUA · RESTASIS · RESTASIS MULTIDOSE · TEVA-CYCLOSPORINE | 4 | 4 | Yes |
| Mercaptamine | CYSTADROPS | 1 | 1 | Yes |
| Voretigene Neparvovec | LUXTURNA | 1 | 1 | Yes |
| Ocriplasmin | JETREA | 2 | 0 | Not in Canada |
| Sodium Chloride, Hypertonic | EYESALINE EYEWASH · MURO 128 OPH SOLN 2% | 2 | 0 | Not in Canada |
| Cenegermin | OXERVATE | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is CEQUA called?
The same molecule, Ciclosporin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| APO-Ciclosporin | Latin | Australia |
| CICLOSPORIN-WGR | Latin | Australia |
| Sandimmun | Latin | Australia, South Africa |
| Atopica vet. | Latin | Iceland |
| Ikervis | Latin | Australia, Czechia, Iceland |
| Neoral | Latin | Australia |
| SANDIMMUN NEORAL | Latin | Bahrain |
| VERKAZIA | Latin | Bahrain, Saudi Arabia |
| Sporimune vet. | Latin | Iceland |
| Ciclohexal Oral Solution | Latin | South Africa |
| CLASGEN | Latin | Saudi Arabia |
| Optimmune vet. | Latin | Iceland |
| Restasis | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.